BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 15967113)

  • 1. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
    Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC
    Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
    Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
    Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
    Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
    Majumder PK; Febbo PG; Bikoff R; Berger R; Xue Q; McMahon LM; Manola J; Brugarolas J; McDonnell TJ; Golub TR; Loda M; Lane HA; Sellers WR
    Nat Med; 2004 Jun; 10(6):594-601. PubMed ID: 15156201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.
    Phillips RJ; Mestas J; Gharaee-Kermani M; Burdick MD; Sica A; Belperio JA; Keane MP; Strieter RM
    J Biol Chem; 2005 Jun; 280(23):22473-81. PubMed ID: 15802268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
    Lu Y; Yu Q; Liu JH; Zhang J; Wang H; Koul D; McMurray JS; Fang X; Yung WK; Siminovitch KA; Mills GB
    J Biol Chem; 2003 Oct; 278(41):40057-66. PubMed ID: 12869565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
    Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
    Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
    Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
    Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways.
    Aeder SE; Martin PM; Soh JW; Hussaini IM
    Oncogene; 2004 Dec; 23(56):9062-9. PubMed ID: 15489897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo.
    Schlegel J; Piontek G; Mennel HD
    Anticancer Res; 2002; 22(5):2837-40. PubMed ID: 12530006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
    Choe G; Horvath S; Cloughesy TF; Crosby K; Seligson D; Palotie A; Inge L; Smith BL; Sawyers CL; Mischel PS
    Cancer Res; 2003 Jun; 63(11):2742-6. PubMed ID: 12782577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
    St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
    Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
    Gu J; Tamura M; Yamada KM
    J Cell Biol; 1998 Nov; 143(5):1375-83. PubMed ID: 9832564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.
    Waldron JS; Yang I; Han S; Tihan T; Sughrue ME; Mills SA; Pieper RO; Parsa AT
    J Clin Neurosci; 2010 Dec; 17(12):1543-7. PubMed ID: 20822910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.
    Abel TW; Baker SJ; Fraser MM; Tihan T; Nelson JS; Yachnis AT; Bouffard JP; Mena H; Burger PC; Eberhart CG
    J Neuropathol Exp Neurol; 2005 Apr; 64(4):341-9. PubMed ID: 15835270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.